Study #2021-0526
Phase I/II Study of CD5 CAR Engineered IL15-Transduced Cord Blood-Derived NK Cells in Conjunction with Lymphodepleting Chemotherapy for the Management of Relapsed/Refractory Hematological Malignancies
MD Anderson Study Status
Enrolling
Treatment Agent
Fludarabine Phosphate, Cyclophosphamide, CAR.5/IL15-transduced CB-NK cells
Description
To determine the safety, efficacy and optimal cell dose of CAR 5/IL15-transduced CB-NK cells in patients with relapsed/refractory T-cell malignances, mantle cell lymphoma, and chronic lymphocytic leukemia. The efficacy and optimal dose will be identified for individual diseases.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Hematological Malignancy
Study phase:
Physician name:
Chitra Hosing
Department:
Stem Cell Transplantation
For general questions about clinical trials:
1-855-773-0951
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.